Leading defamation lawyer Patrick George has joined Company (Giles), reuniting with former protégé Rebekah Giles after leaving the law firm he founded 17 years ago.
Eleven current and former Star Entertainment executives have refuted ASIC’s claims that they breached their duties in relation to the casino operator’s lax money laundering compliance, with all but two denying they had a duty to ensure the company complied with its legal obligations.
Insurer Bond & Credit Company has overcome an administrator’s protests and won leave to bring cross-claims against three Greensill entities in lawsuits over the financing firm’s $1.7 billion collapse.
A shareholder class action against Medibank has claimed it did not disclose “serious deficiencies” in its cybersecurity measures, including failing to implement security measures such as multi factor authentication, causing investors to buy shares at inflated prices.
Australia’s largest private health insurer Medibank has been hit with a shareholder class action in the wake of a massive cyberattack that left the data of 10 million customers exposed.
Property and hotel giant Meriton is the latest company to fall victim to a cybersecurity breach, which exposed information held by the company on almost 2,000 guests and staff.
The NSW state racing authority has won access to communications between public relations firm Cato & Clive and five other racing bodies, including Racing Victoria, as it weighs a lawsuit alleging they plotted to exclude the body from the Australian horseracing industry.
A unit of Purdue Pharma has fired off a cross-claim in Australian drug maker AUPharma’s lawsuit alleging the US drug giant was wrongly granted patent extensions for oxycodone products marketed as Targin.
Port operations provider Engage Marine is seeking to obtain copies of restricted documents in the ACCC’s case against TasPorts, as it mounts its own competition suit against the Tasmanian government-owned body.
Beauty giant McPherson’s has denied ASIC’s claims that it misled the market and breached its disclosure obligations in 2020, arguing that a document showing sales of its Dr LeWinn’s line were down by $21 million was a draft that couldn’t have been used to revise a financial forecast.